WO2015127955A1 - A new polymorph of tiacumicin b and process for preparation thereof - Google Patents

A new polymorph of tiacumicin b and process for preparation thereof Download PDF

Info

Publication number
WO2015127955A1
WO2015127955A1 PCT/EP2014/053619 EP2014053619W WO2015127955A1 WO 2015127955 A1 WO2015127955 A1 WO 2015127955A1 EP 2014053619 W EP2014053619 W EP 2014053619W WO 2015127955 A1 WO2015127955 A1 WO 2015127955A1
Authority
WO
WIPO (PCT)
Prior art keywords
tiacumicin
organic solvent
crystalline polymorph
process according
isopropanol
Prior art date
Application number
PCT/EP2014/053619
Other languages
French (fr)
Inventor
Piera Fonte
Giovanni Lazzari
Original Assignee
Olon S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olon S.P.A. filed Critical Olon S.P.A.
Priority to PCT/EP2014/053619 priority Critical patent/WO2015127955A1/en
Publication of WO2015127955A1 publication Critical patent/WO2015127955A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a solid state form of Tiacumicin B and to a process for preparing said solid state form.
  • the process according to this invention is more efficient than methods known in the art and is easily scalable for commercial production.
  • Tiacumicin B belongs to the family of Tiacumicins; Tiacumicins, produced by fermentation of Dactylosporangium aurantiacum, are a group of unsaturated 18-membered macrocyclic of the macrolide class that differ in the type of substituents of the unsaturated ring. Tiacumicin B has the structure shown below in the following Formula (I):
  • Tiacumicins and in particular Tiacumicin B show activity against a variety of bacterial pathogens including Clostridium difficile.
  • the Lipiarmycins are another class of product closely related to the Tiacumicins.
  • Tiacumicin B is identical to Lipiarmycin A3.
  • the present inventions provides an improved crystallization method for Tiacumicin B that surprisingly results in a new polymorphic form namely Form II.
  • the method according to the inventions is simpler than those described in the prior art and preserves the quality of the product. This provides a new opportunity to improve and facilitate the handling and storage of Tiacumicin B as active ingredients.
  • the object of this invention is a new form of Tiacumicin B called Form II.
  • Crystalline Form II of Tiacumicin B has the DSC diagram shown in Figure 4, characterized by a endothermic peak at 144.67°C in the DSC diagram.
  • Form II has the X ray powder diffractogram (X PD) shown in Figure 5, characterized by a system of main diffraction peaks expressed in 2-theta degree [°] at 3.31 ⁇ 0.2 - 6.65 ⁇ 0.2 -7.38 ⁇ 0.2 - 8.3 ⁇ 0.2 - 9.92 ⁇ 0.2 - 10.42 ⁇ 0.2 - 12.07 ⁇ 0.2 - 12.8 ⁇ 0.2 - 13.22 ⁇ 0.2-13.95 ⁇ 0.2 -14.22 - 14.26 ⁇ 0.2 - 15.62 ⁇ 0.2 - 18.6 ⁇ 0.2 - 19.77 ⁇ 0.2 - 20.92 ⁇ 0.2.
  • Another object of the present invention is a method for obtaining Form II of Tiacumicin B by means of crystallization of crude Tiacumicin B and heating at 60°C-80°C in a suitable organic solvent.
  • Fig. 1 DSC diagram of Tiacumicin B Form I
  • Fig. 2 XRPD diffractogram of Tiacumicin B Form I
  • Fig. 3 IR spectrum of Tiacumicin B Form I
  • Fig. 4 DSC diagram of Tiacumicin B Form II
  • Fig. 5 XRPD diffractogram of Tiacumicin B Form II DETAILED DESCRIPTION OF THE INVENTIONS
  • Crude Tiacumicin B can be obtained according to known methods described in the art (U.S. Pat. No. 3,978,21 1 ; U.S. Pat. No. 7,507,564; MI2012A001406; MI2012A000560).
  • Crude Tiacumicin B can be obtained for example trough a process comprising the steps of:
  • Tiacumicin B can be obtained in two distinct polymorphic forms, herein called Form I and Form II.
  • Polymorphic form I of Tiacumicin B is the form known to the skilled person which is cited in the prior art (U.S. Pat. No. 3,978,21 1); Polymorphic form II of Tiacumicin B is the object of this invention.
  • the two different polymorphic modifications are selectively obtainable by suitably adjusting the conditions applied in the crystallisation process.
  • Form I of Tiacumicin B differs considerably from the form we obtained and called Form II, in terms of the chemical-physical properties analysed (DSC, X PD diffractograms).
  • Another object of this invention is a process for preparing the crystalline Form II of Tiacumicin B as defined above, comprising the steps of:
  • the solvent is a polar organic solvent, such as propanol, acetone, acetonitrile and isopropanol, preferably the solvent is isopropanol.
  • Crude Tiacumicin B is obtained by methods known in the art (U.S. Pat. No. 3,978,21 1 ; U.S. Pat. No. 7,507,564; MI2012A001406; MI2012A000560).
  • a further object of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising the crystalline Form II of Tiacumicin B as above defined and a pharmaceutically acceptable excipient.
  • Said pharmaceutical composition can be used in treating or preventing bacterial infections in a mammal.
  • Crude Tiacumicin B was added of isopropanol at a concentration of about 300 g/1. The resulting suspension, placed under stirring, was heated at 65°C; The solid product completely dissolved. The solution was cooled at room temperature and then at 4°C. The solid obtained was dried under vacuum over night.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention refers to acrystalline polymorph form (Form II) of Tiacumicin B and to a process for preparing said solid state form. The process according to this invention is more efficient than methods known in the art and is easily scalable for commercial production.

Description

A NEW POLYMORPH OF TIACUMICIN B AND PROCESS FOR
PREPARATION THEREOF
FIELD OF THE INVENTIONS
The present invention relates to a solid state form of Tiacumicin B and to a process for preparing said solid state form. The process according to this invention is more efficient than methods known in the art and is easily scalable for commercial production.
BACKGROUND
Tiacumicin B belongs to the family of Tiacumicins; Tiacumicins, produced by fermentation of Dactylosporangium aurantiacum, are a group of unsaturated 18-membered macrocyclic of the macrolide class that differ in the type of substituents of the unsaturated ring. Tiacumicin B has the structure shown below in the following Formula (I):
Figure imgf000002_0001
Tiacumicins and in particular Tiacumicin B show activity against a variety of bacterial pathogens including Clostridium difficile.
The Lipiarmycins are another class of product closely related to the Tiacumicins. In particular Tiacumicin B is identical to Lipiarmycin A3.
Lipiarmycin was first isolated from Actinoplanes deccanensis in the 1970s. The earliest patent by Lepetit U.S. Pat. No. 3,978,21 1 already described an anhydrous crystalline form of Lipiarmycin. Even if the PX D are not reported in said patent, however the melting point and infrared spectra are reported. This is sufficient to identify univocally the crystalline form (herein defined as Form I). In the above mentioned patent example of crystallization a procedure is described with anhydrous organic solvents leading anhydrous crystalline form of Tiacumicin B, as demonstrated by DSC data related to a product obtained with the same procedure and included in the present invention (Figure 1).
US 7,378,508 and its European counterpart EP 2 125 850 Bl disclose different crystalline forms of Tiacumicin B, namely Form A, Form B and amorphous. US 2013/0303472 claims three additional crystalline forms of which two are solvated (forms Z and Zl) and one anhydrous non solvated -form (form C).
The processes described in the prior art suffer for some drawbacks: in US 7,378,508 the procedure requires about 3 to about 14 days, therefore it is not suitable for industrial application. In patent application US 2013/0303472, more suitable processes are described, but on the other hand they require high stressed drying conditions. It is known, as described in US 2008/0176927, that Tiacumicins have stability issues and therefore high temperature drying (> of 40°C) lead to degradation of the molecule. Therefore neither the procedure described in the US 7,378,508, nor the procedure described in the application US 2013/0303472 are suitable for commercial production.
It is known that the occurrence of active ingredients in different crystal polymorphs (polymoφhism) is of great significance both for development of preparation processes and for development of formulations. Different crystal polymorphs of a chemical compound, in addition to appearance (crystal habit) and hardness, also differ in numerous further physicochemical properties, like for example stability, filterability, solubility and hygroscopicity. Thus a given crystalline form of a particular API often constitutes an important determinant of the API's ease of preparation, stability, solubility, shelf-life, ease of formulation, rate of the dissolution in the gastrointestinal tract and other fluids, and in vivo bioavailability. Choice of a crystalline form will depend on a comparison of physical properties variables of the different forms.
The present inventions provides an improved crystallization method for Tiacumicin B that surprisingly results in a new polymorphic form namely Form II. The method according to the inventions is simpler than those described in the prior art and preserves the quality of the product. This provides a new opportunity to improve and facilitate the handling and storage of Tiacumicin B as active ingredients.
SUMMARY
The object of this invention is a new form of Tiacumicin B called Form II.
Crystalline Form II of Tiacumicin B has the DSC diagram shown in Figure 4, characterized by a endothermic peak at 144.67°C in the DSC diagram.
Form II has the X ray powder diffractogram (X PD) shown in Figure 5, characterized by a system of main diffraction peaks expressed in 2-theta degree [°] at 3.31± 0.2 - 6.65 ± 0.2 -7.38 ± 0.2 - 8.3 ± 0.2 - 9.92 ± 0.2 - 10.42 ± 0.2 - 12.07 ± 0.2 - 12.8 ± 0.2 - 13.22 ± 0.2-13.95 ± 0.2 -14.22 - 14.26 ± 0.2 - 15.62 ± 0.2 - 18.6 ± 0.2 - 19.77 ± 0.2 - 20.92 ± 0.2.
Another object of the present invention is a method for obtaining Form II of Tiacumicin B by means of crystallization of crude Tiacumicin B and heating at 60°C-80°C in a suitable organic solvent.
BRIEF DESCRIPTION OF FIGURES
Fig. 1 : DSC diagram of Tiacumicin B Form I
Fig. 2: XRPD diffractogram of Tiacumicin B Form I
Fig. 3 : IR spectrum of Tiacumicin B Form I
Fig. 4: DSC diagram of Tiacumicin B Form II
Fig. 5: XRPD diffractogram of Tiacumicin B Form II DETAILED DESCRIPTION OF THE INVENTIONS
Crude Tiacumicin B can be obtained according to known methods described in the art (U.S. Pat. No. 3,978,21 1 ; U.S. Pat. No. 7,507,564; MI2012A001406; MI2012A000560).
Crude Tiacumicin B can be obtained for example trough a process comprising the steps of:
a) Filtration of the fermentation broth
b) Absorption to a HIC resin followed by elution
c) Insolubilization to afford crude Tiacumicin B
It has now been found that, depending on the crystallization conditions of the crude product, Tiacumicin B can be obtained in two distinct polymorphic forms, herein called Form I and Form II.
Polymorphic form I of Tiacumicin B is the form known to the skilled person which is cited in the prior art (U.S. Pat. No. 3,978,21 1); Polymorphic form II of Tiacumicin B is the object of this invention.
The two different polymorphic modifications are selectively obtainable by suitably adjusting the conditions applied in the crystallisation process.
It has also found that the two different polymorphs can be inter-converted from Form I to Form II and vice versa by applying suitable re-crystallisation conditions.
In particular, by operating as described in the U.S. Pat. No. 3,978,21 1 an anhydrous crystalline Tiacumicin B with the following characteristics is obtained:
1) a DSC diagram as shown in Figure 1, characterised by a endothermic peak at 179,81°C an XRPD diffractograms shown in Figure 2, characterised by a system of main peaks expressed in 2-theta degrees [°] at 3,3± 0,2 - 6,74 ± 0,2 - 7,83 ± 0,2 -9,94 ± 0,2 - 10,14 ± 0,2 - 12,1 ± 0,2 - 13,22 ± 0,2 - 13,76 ± 0,2 - 14,5 ± 0,2 - 14,97 ± 0,2 - 18,78 ± 0,2 - 19,9± 0,2 - 20,22 ± 0,2 - 21 ± 0,2.
2) the IR spectrum shown in Figure 3 3) a melting point of 173°C.
The data clearly demonstrate that the product obtained following the process reported in literature corresponds to Form I of anhydrous crystalline Tiacumicin B, known to the prior art.
It is also evident that the obtained Form I of Tiacumicin B differs considerably from the form we obtained and called Form II, in terms of the chemical-physical properties analysed (DSC, X PD diffractograms).
Object of the present invention is the polymorphic Form II of Tiacumicin B which in pure anhydrous crystalline form has the following characteristics:
1) a DSC diagram as shown in Figure 4, characterised by a endothermic peak at 144,67°C
2) an XRPD diffractograms shown in Figure 5, characterised by a system of main peaks expressed in 2-theta degrees [°] 3,31± 0,2 - 6,65 ± 0,2 -7,38 ± 0,2 - 8,3 ± 0,2 - 9,92 ± 0,2 - 10,42 ± 0,2 - 12,07 ± 0,2 - 12,8 ± 0,2 - 13,22 ± 0,2 - 13,95 ± 0,2 - 14,22-14,26 ± 0,2 - 15,62 ± 0,2 -18,6 ± 0,2 - 19,77 ± 0,2 - 20,92 ± 0,2.
Another object of this invention is a process for preparing the crystalline Form II of Tiacumicin B as defined above, comprising the steps of:
a) dissolving Tiacumicin B in an organic solvent under stirring at the reflux temperature, until the product has completely dissolved;
b) cooling the solution first at room temperature and then at 4°C to complete crystallisation.
Preferably the solvent is a polar organic solvent, such as propanol, acetone, acetonitrile and isopropanol, preferably the solvent is isopropanol.
Crude Tiacumicin B is obtained by methods known in the art (U.S. Pat. No. 3,978,21 1 ; U.S. Pat. No. 7,507,564; MI2012A001406; MI2012A000560).
A further object of the present invention is a pharmaceutical composition comprising the crystalline Form II of Tiacumicin B as above defined and a pharmaceutically acceptable excipient. Said pharmaceutical composition can be used in treating or preventing bacterial infections in a mammal.
Example 1: Preparation of Tiacumicin B Form I (comparative example)
Crude Tiacumicin B was dissolved in methanol at a concentration of 200 g/1. The resulting solution was loaded onto a column packed with HP20SS resin (1 1-50x5 cm) that had previously been equilibrated with 5 Bed volumes (BV) of acetate buffer at pH 5,0. The column was washed with 10 BV of acetonitrile in acetate buffer pH 6,0 (the % of acetonitrile ranges from 10% to 30%). Tiacumicin B was eluted with 5 BV acetonitrile in acetate buffer pH 6,0 (the % of acetonitrile ranges from 30% to 45%). The column eluate was divided into fractions and each fraction was analyzed by HPLC to assess purity. Fractions with a purity greater than 95% were pooled and concentrated; the concentrate was extracted with ethyl acetate. The ethyl acetate layer was washed with 2 volumes of water, concentrated to yield a oil. The resulting oil from the previous step was dissolved in methanol; the solution is warmed and added of diethyl ether and n-pentane. The solution was cooled and filtered. The solid was dried under vacuum over night.
XRPD diffractograms system of main peaks expressed in 2-theta degrees [°] at 3,3 ± 0,2 - 6,74 ± 0,2 - 7,83 ± 0,2 - 9,94 ± 0,2 - 10,14 ± 0,2 - 12,1 ± 0,2 - 13,22 ± 0,2 - 13,76 ± 0,2 - 14,5 ± 0,2 - 14,97 ± 0,2 - 18,78 ± 0,2 - 19,9 ± 0,2 - 20,22 ± 0,2 - 21 ± 0,2. Melting point of 173°C.
Example 2: Preparation of Tiacumicin B Form II
Crude Tiacumicin B was added of isopropanol at a concentration of about 300 g/1. The resulting suspension, placed under stirring, was heated at 65°C; The solid product completely dissolved. The solution was cooled at room temperature and then at 4°C. The solid obtained was dried under vacuum over night.
XRPD diffractograms system of main peaks expressed in 2-theta degrees [°]
3,31 ± 0,2 - 6,65 ± 0,2 - 7,38 ± 0,2 - 8,3 ± 0,2 - 9,92 ± 0,2 - 10,42 ± 0,2 - 12,07 ± 0,2 - 12,8 ± 0,2 -1 3,22 ± 0,2 - 13,95 ± 0,2 - 14,22-14,26 ± 0,2 - 15,62 ± 0,2 - 18,6 ± 0,2 - 19,77 ± 0,2 - 20,92 ± 0,2. Endothermic peak at 144,67°C.

Claims

1. A crystalline polymorph form (Form II) of Tiacumicin B characterized by a XRPD diffractogram system of main peaks expressed in 2-theta degrees [°] 3.31 ± 0.2 - 6.65 ± 0.2 - 7.38 ± 0.2 - 8.3 ± 0.2 - 9.92 ± 0.2 - 10.42 ± 0.2 - 12.07 ± 0.2 - 12.8 ± 0.2 - 13.22 ± 0.2 - 13.95 ± 0.2 - 14.22 - 14.26 ± 0.2 - 15.62 ± 0.2 -18.6 ± 0.2 - 19.77 ± 0.2 - 20.92 ± 0.2.
2. The crystalline polymorph form of claim 1 further characterized by a DSC endothermic peak at 144.67°C.
3. A pharmaceutical composition comprising the crystalline polymorph of claim 1 or claim 2 an a pharmaceutically acceptable excipient.
4. A pharmaceutical composition according to claim 3 for use in treating or preventing bacterial infections in a mammal.
5. A process for preparing the crystalline polymorph form (Form II) of Tiacumicin B as defined in claim 1 or 2, comprising the steps of:
a) dissolving Tiacumicin B in an organic solvent under stirring at the reflux temperature, until the product has completely dissolved;
b) cooling the solution first at room temperature and then at 4°C to complete crystallisation.
6. The process according to claim 5 wherein the organic solvent is a polar organic solvent.
7. The process according to claim 6 wherein the organic solvent is selected from the group comprising propanol, acetone, acetonitrile and isopropanol.
8. The process according to claim 7 wherein the organic solvent is isopropanol.
PCT/EP2014/053619 2014-02-25 2014-02-25 A new polymorph of tiacumicin b and process for preparation thereof WO2015127955A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/053619 WO2015127955A1 (en) 2014-02-25 2014-02-25 A new polymorph of tiacumicin b and process for preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/053619 WO2015127955A1 (en) 2014-02-25 2014-02-25 A new polymorph of tiacumicin b and process for preparation thereof

Publications (1)

Publication Number Publication Date
WO2015127955A1 true WO2015127955A1 (en) 2015-09-03

Family

ID=50288035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/053619 WO2015127955A1 (en) 2014-02-25 2014-02-25 A new polymorph of tiacumicin b and process for preparation thereof

Country Status (1)

Country Link
WO (1) WO2015127955A1 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978211A (en) 1973-11-22 1976-08-31 Gruppo Lepetit S.P.A. Lipiarmycin and its preparation
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
US7507564B2 (en) 2002-07-29 2009-03-24 Optimer Pharmaceuticals, Inc. Tiacumicin production
CN103275153A (en) * 2013-06-27 2013-09-04 华北制药集团新药研究开发有限责任公司 Preparation method of fidaxomicin crystal
CN103320355A (en) * 2013-05-29 2013-09-25 华北制药集团新药研究开发有限责任公司 Actinoplanessp. strain and its use in preparation of fidaxomicin
ITMI20120560A1 (en) 2012-04-05 2013-10-06 Olon Spa PROCEDURE FOR THE PURIFICATION OF TIACUMICINA B
US20130303472A1 (en) 2012-05-10 2013-11-14 Tamas FONAGY Solid state forms of fidaxomycin and processes for preparation thereof
WO2013170142A1 (en) * 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
ITMI20121406A1 (en) 2012-08-07 2014-02-08 Olon Spa PROCEDURE FOR THE PRODUCTION OF TIACUMICINA B

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978211A (en) 1973-11-22 1976-08-31 Gruppo Lepetit S.P.A. Lipiarmycin and its preparation
US7507564B2 (en) 2002-07-29 2009-03-24 Optimer Pharmaceuticals, Inc. Tiacumicin production
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
EP2125850A1 (en) 2007-01-22 2009-12-02 Optimer Pharmaceuticals, Inc. Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
ITMI20120560A1 (en) 2012-04-05 2013-10-06 Olon Spa PROCEDURE FOR THE PURIFICATION OF TIACUMICINA B
US20130303472A1 (en) 2012-05-10 2013-11-14 Tamas FONAGY Solid state forms of fidaxomycin and processes for preparation thereof
WO2013170142A1 (en) * 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
ITMI20121406A1 (en) 2012-08-07 2014-02-08 Olon Spa PROCEDURE FOR THE PRODUCTION OF TIACUMICINA B
CN103320355A (en) * 2013-05-29 2013-09-25 华北制药集团新药研究开发有限责任公司 Actinoplanessp. strain and its use in preparation of fidaxomicin
CN103275153A (en) * 2013-06-27 2013-09-04 华北制药集团新药研究开发有限责任公司 Preparation method of fidaxomicin crystal

Similar Documents

Publication Publication Date Title
US8258327B2 (en) Crystalline minocycline base and processes for its preparation
US9233318B2 (en) Purification method of azacyclohexapeptide or its salt
US20190194146A1 (en) 6-bromo-3-hydroxy-2-pyrazinecarboxamide crystal and method for producing same
US20200087282A1 (en) Salt of substituted piperidine compound
WO2012150561A1 (en) Rifaximin dimethylformamide solvate
US9624207B2 (en) Polymorphs of azilsartan medoxomil
WO2017021975A1 (en) Process for the preparation of crystalline forms of rifaximin
CN111072572B (en) Crystal forms of hydrogen sulfate of Elagolix key intermediate, preparation and application thereof
WO2015011659A1 (en) Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
WO2015127955A1 (en) A new polymorph of tiacumicin b and process for preparation thereof
WO2014195977A2 (en) Novel polymorphs of vismodegib
AU2016324121B2 (en) New crystal of piperazine compound
EP4188905B1 (en) Method for the purification of vilanterol trifenatate
CN114685479B (en) Oxazolidinone compound as well as preparation method and application thereof
US20230286898A1 (en) Method for the purification of vilanterol trifenatate
US20050059653A1 (en) Novel crystalline forms of 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b: 2',3'-e][1,4] diazepin-6-one (nevirapine)
WO2005121062A2 (en) Process for the preparation of pravastatin
EP1907406B1 (en) Crystalline forms of macrolide compounds endowed with antiinflammatory activity
EP2610239A1 (en) Preparation Of Rasagiline Hemitartrate
KR20110013375A (en) Highly pure pentamycin
US20150291574A1 (en) Novel polymorphs of azilsartan
WO2016038590A1 (en) Process for the preparation of crystalline form i of regorafenib
WO2014024210A2 (en) Novel polymorphs of doxercalciferol
CN106187905A (en) Crystal form of Ding Luta amine and preparation method thereof
CN106008497A (en) Apixaban crystal form and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710511

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14710511

Country of ref document: EP

Kind code of ref document: A1